Clinical Trials Browser

Phase 2 × Breast Neoplasms × taletrectinib × Clear all

NCT06214793 2025-05-01

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)

Phase 2 Suspended

Breast Neoplasms